Non-Targeted Metabolomics Reveal Apomorphine’s Therapeutic Effects and Lysophospholipid Alterations in Steatohepatitis

Non-Targeted Metabolomics Reveal Apomorphine’s Therapeutic Effects and Lysophospholipid Alterations in Steatohepatitis

Metabolic dysfunction-associated steatohepatitis (MASH), characterized by progressive inflammation and fibrosis, evolves from metabolic dysfunction-associated steatotic liver disease and significantly heightens the risk of cirrhosis and hepatocellular carcinoma. Understanding metabolic pathways that...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hideo Ogiso, Kouichi Miura, Ryozo Nagai, Hitoshi Osaka, Kenichi Aizawa
Format:	Article
Language:	English
Published:	MDPI AG 2024-10-01
Series:	Antioxidants
Subjects:	metabolic dysfunction-associated steatohepatitis non-alcoholic steatohepatitis PTEN knockout apomorphine lysophospolipid lysophosphatidylcholine
Online Access:	https://www.mdpi.com/2076-3921/13/11/1293
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Targeted Plasma Bile Acid Metabolomic Analysis in Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Hepatitis
by: Yuta Hirata, et al.
Published: (2024-12-01)

Application of ursodeoxycholic acid at non-alcoholic and alcohol-induced steatohepatitis
by: Ye. A. Fedos’ina, et al.
Published: (2010-06-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)

Combination of autoimmune hepatitis to non-alcoholic steatohepatitis (Clinical case)
by: A. A. Driga, et al.
Published: (2010-11-01)

A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use
by: Abdul Haseeb Hasan, et al.
Published: (2025-01-01)

Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study
by: Yestle Kim, et al.
Published: (2024-11-01)

Prevention of medication errors in healthcare transition of patients treated with apomorphine
by: M. Ucha Sanmartin, et al.
Published: (2014-05-01)

Unraveling the Beneficial Role of Resveratrol in Fructose-Induced Non-Alcoholic Steatohepatitis with a Focus on the AMPK/Nrf2 Signaling Axis
by: Soha S. Zakaria, et al.
Published: (2025-01-01)

Anti-CD122 antibody restores specific CD8+ T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth
by: Stéphanie Lacotte, et al.
Published: (2023-12-01)

Diagnostics of progression of liver fibrosis in patients with non-alcoholic steatohepatitis combined with obesity and chronic calculous cholecystitis.
by: A. Yu. Filippova
Published: (2020-04-01)

Utility of blood parameters in predicting oesophageal varices in patients with liver cirrhosis
by: Cyrin Annie Cyriac, et al.
Published: (2024-11-01)

Ultrasound radiomics-based logistic regression model for fibrotic NASH
by: Fei Xia, et al.
Published: (2025-02-01)

The impact of the ursodeoxycholic acid as monotherapy and in the combination with the lactulose on the biochemical blood tests values of the nonalcoholic steatohepatitis patients
by: I. V. Mayev, et al.
Published: (2013-03-01)

Sulforaphane ameliorates non-alcoholic steatohepatitis by KLF4-mediated macrophage M2 polarization
by: Xianghui Huang, et al.
Published: (2024-09-01)

The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials
by: Adnan Malik, et al.
Published: (2022-01-01)

Clinical characteristics of patients with hepatic steatosis and non-alcoholic steatohepatitis combined with obesity and disorders of the biliary tract, depending on the body mass index.
by: A. Yu. Filippova
Published: (2016-03-01)

Clinical characteristics of patients with hepatic steatosis and non-alcoholic steatohepatitis combined with obesity and disorders of the biliary tract, depending on the body mass index
by: Filippova A.Yu.
Published: (2016-03-01)

Editorial: Mechanistic insight and therapeutic potential for the management of non-alcoholic steatohepatitis (NASH)
by: Umashanker Navik, et al.
Published: (2024-11-01)

Effects of Metabolic Dysfunction–Associated Steatohepatitis in Alertness, Associative Learning, and Astrocyte Density
by: Sara G. Higarza, et al.
Published: (2025-01-01)

Corrigendum: Editorial: Mechanistic insight and therapeutic potential for the management of non-alcoholic steatohepatitis (NASH)
by: Umashanker Navik, et al.
Published: (2024-12-01)

Possibilities of correction of lipid-phospholipid disorders in patients with non-alcoholic steatohepatitis against obesity and pathology of the biliary tract.
by: A. Yu. Filippova
Published: (2019-11-01)

Sleeve-gastrectomy results in improved metabolism and a massive stress response of the liver proteome in a mouse model of metabolic dysfunction-associated steatohepatitis
by: Andreas Kroh, et al.
Published: (2024-11-01)

Principles of management of patient with asymptomatic elevation of serum aminotransferases
by: Ye. N. German, et al.
Published: (2011-02-01)

Body Composition and Progression of Biopsy‐Proven Non‐Alcoholic Fatty Liver Disease in Patients With Obesity
by: Qianyi Wan, et al.
Published: (2024-12-01)

Impaired postprandial GLP-2 response enhances endotoxemia, systemic inflammation, and kidney injury in metabolic dysfunction-associated steatohepatitis (MASH): effect of phospholipid curcumin meriva
by: Giovanni Musso, et al.
Published: (2024-12-01)

Two faces of the same coin non alcoholic fatty liver disease; with and without diabetes: Comparative clinico pathological analysis: A cross sectional observational study
by: Syed Mushfiq, et al.
Published: (2025-01-01)

Methodical approaches in experimental modelling of non-alcoholic fatty liver disease
by: N. V. Bivalkevich, et al.
Published: (2015-09-01)

CISD2-mediated mitochondrial dysfunction and iron redistribution contributes to ferroptosis in arsenic-induced nonalcoholic steatohepatitis
by: Jingyuan Zhang, et al.
Published: (2025-01-01)

Imeglimin Halts Liver Damage by Improving Mitochondrial Dysfunction in a Nondiabetic Male Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis
by: Kosuke Kaji, et al.
Published: (2024-11-01)

Cholesterol overload in macrophages drives metabolic dysfunction-associated steatohepatitis via inhibiting 7-dehydrocholesterol reductase in mice
by: Xiaoxiao Li, et al.
Published: (2024-11-01)

Epidemiologic features of non-alcoholic fatty liver disease in Russia
by: O. M. Drapkina, et al.
Published: (2014-10-01)

Identification of biomarkers for the diagnosis in colorectal polyps and metabolic dysfunction-associated steatohepatitis (MASH) by bioinformatics analysis and machine learning
by: Ying Geng, et al.
Published: (2024-11-01)

Non-Alcoholic Fatty Liver Disease, Bile Acids and Intestinal Microbiota
by: R. V. Maslennikov, et al.
Published: (2018-09-01)

TEC-mediated tRF-31R9J regulates histone lactylation and acetylation by HDAC1 to suppress hepatocyte ferroptosis and improve non-alcoholic steatohepatitis
by: Juanjuan Zhu, et al.
Published: (2025-01-01)

E2F2 Reprograms Macrophage Function By Modulating Material and Energy Metabolism in the Progression of Metabolic Dysfunction‐Associated Steatohepatitis
by: Zheng Liu, et al.
Published: (2024-12-01)

Steatohepatitis-induced vascular niche alterations promote melanoma metastasis
by: Johannes Hoffmann, et al.
Published: (2025-01-01)

Detectability of Liver Steatosis and Fibrosis with Transient Elastography and Controlled Attenuation Parameter in Residents of St. Petersburg
by: V. P. Kovyazina, et al.
Published: (2021-04-01)

Features of eating behavior in children with different forms of non-alcoholic fatty liver disease
by: Yu.M. Stepanov, et al.
Published: (2021-09-01)

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Jessica M. Rubino, et al.
Published: (2025-01-01)

Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results
by: V. T. Ivashkin, et al.
Published: (2015-12-01)